The use of pembrolizumab as monotherapy is recommended in patients with metastatic, recurrent, or persistent CC, of squamous, adenocarcinoma, or adenosquamous histology, with progression on at least one line of platinum-based chemotherapy (PD-L1 CPS ≥1%, MSI-H, dMMR, TMB-H). This evidence concerns the gene CD274 and adenocarcinoma.